Human and equine cell transplant strategies for cartilage lesions usually result in scar tissue that is similar to what is produced naturally during the repair process. In this study, culture-expanded de-differentiated chondrocytes and primary bone marrow stromal cells at a pre-transplantation time-point were compared along with neonatal cartilage to repair tissue. Transcriptional profiling using a 9413-probeset equine-specific cDNA microarray and targeted real-time quantitative polymerase chain reaction validation were used to characterize relationships between these cell types and repair tissue both broadly and for individual cartilage biomarkers. The greatest divergence in expression was detected for transcripts encoding matrix proteins that typically define the differentiation status of normal articular cartilage and fibrocartilage repair tissue. Expression patterns and gene ontology analyses indicated that while the repair cells were more chondrogenic than bone marrow stromal cells and de-differentiated cultured chondrocytes, steady-state levels of transcripts encoding cartilage biomarkers were substantially lower than the amounts found in neonatal articular cartilage. By characterizing gene expression differences amongst these tissues, we present important targets to monitor when developing improvements to cartilage engineering therapies.
INTRODUCTION
Repair tissue that forms in full-thickness articular cartilage lesions is often described as fibrocartilage or hyaline-like cartilage. The fibrocartilage typically contains more type I collagen than type II collagen, and is deficient in proteoglycans relative to normal articular cartilage [1] [2] [3] . Repair tissue is stiff and unable to meet the biomechanical demands imposed upon an articular surface with motion [4, 5] . Additionally, repair tissue fails to fully anchor or attach to the surrounding articular cartilage. As a result, the ultimate outcome is often fibrillation of repair tissue, and even full detachment and separation from the cartilage surrounding the area of the lesion [6] . Previous studies have demonstrated that while cells of articular repair tissue may also be of mesenchymal origin, they do not successfully recapitulate differentiation to the chondrogenic phenotype of normal articular chondrocytes during the healing process [6, 7] . Thus, differences in matrix composition and organization between repair tissue and normal articular cartilage provide an explanation for the structural and biomechanical inability of repair tissue to maintain an articular surface that can function adequately with the challenges to which it is subjected.
Since naturally forming repair tissue does not adequately replace cartilage, therapeutic approaches have been developed utilizing chondrocytes and their precursors in tissue engineering strategies. Chrondrocytes are harvested from cartilage, expanded in monolayer culture, and then transplanted into lesions [8] . However, following the culture period, these cells have de-differentiated with greatly reduced expression of type II collagen and other cartilage matrix proteins compared to primary articular chondrocytes [9] . The resulting clinical outcome for patients is variable, with repair tissue failing to regenerate the structural or functional properties of normal hyaline cartilage [10] . To improve upon results of autologous chondrocyte implantation, biopsyaspirated and culture flask-adherent bone marrow stromal cells (BMSCs) have also become a popular option for implantation into articular lesions because they are easier to access than chondrocytes, are of the same mesodermal origin, and they possess multipotent capabilities including chondrocyte differentiation [11] [12] [13] [14] [15] [16] . Yet with full-thickness articular lesions and microfracture surgery into the subchondral bone, these same BMSCs contribute to naturally forming repair tissue which synthesizes a biomechanically inadequate matrix [6, 7] . Unlike repair tissue, the cells of neonatal cartilage express high levels of type II collagen matrix and display active growth and matrix adaptation [1] [2] [3] [17] [18] [19] [20] . A favorable tissue engineering strategy would include implantation of a cell population capable of gene expression profiles like that of immature or neonatal cartilage, yet within the milieu of a lesion in an adult patient [21] [22] [23] .
To further analyze cell preparations used clinically in repair strategies for articular cartilage lesions, transcriptional profiling was used to address three objectives. First, determine if the expression profile of repair tissue more closely matches one of the three cell populations. Second, compare gene expression in de-differentiated chondrocytes and BMSCs-after harvest and expansion as with transplantation-to cells within repair tissue of a full thickness lesion with microfracture. Third, compare highly anabolic neonatal articular cartilage to repair tissue in a full thickness lesion with microfracture. Differential gene expression was assessed across a large subset of genes in the equine genome, along with targeted transcripts encoding established biomarkers of cartilage.
METHODS

Sample harvesting
Full-thickness neonatal articular cartilage was harvested and pooled from the proximal and distal humerus, the proximal and distal femur, the proximal and distal tibia, proximal radius, and proximal ulna of each foal individually. Pooled cartilage was snap frozen in liquid nitrogen for each of the four 0-10-day-old foals, thus representing four biological replicates. All samples were collected immediately postmortem using protocols approved by the University of Kentucky's Institutional Animal Care and Use Committee (IACUC) from foals euthanized at their owner's request due to health reasons unrelated to joint disease or systemic illness. Particular attention was paid to avoid the epiphyseal cartilage located just below the articular layer which contains blood vessels, is destined to undergo hypertrophic differentiation, and will be replaced by bone from the secondary center of ossification. Repair tissue was collected from defects made in the medial femoral condyles of the femorotibial joints from four adult horses (2-3 years) as previously described [7, 24, 25] , also representing four biological replicates. Briefly, full-thickness lesions were generated in articular cartilage with microfracture penetration into the subchondral bone. Repair tissue was harvested at the 4-month post-operative time-point. The samples were rinsed in sterile phosphate-buffered saline, snap-frozen in liquid nitrogen, and stored at À80 C. For culture of de-differentiated articular chondrocytes (c-DDACs), full-thickness articular cartilage was harvested immediately postmortem from four adult (3-5 years) horses using IACUC approved protocols. For each horse, chondrocytes were enzymatically isolated from the cartilage matrix and cryopreserved as described in Stewart et al. [26] . For the preparation of c-DDAC samples, isolated cells stored in 1-ml aliquots were thawed at 37 C and rinsed in 5 ml warmed medium [OPTI-MEM, 5% fetal bovine serum, 1% L-glutamine, 25 mg/ml L-ascorbic acid phosphate (Wako Chemicals USA, Richmond, VA), 50 U/ml penicillin and 50 mg/ml streptomycin]. Cells were pelleted (360g, 10 min), resuspended in 5 ml of new medium, and seeded in T-75 culture flasks (Corning) at 0.5 million cells per flask. Monolayer cultures were maintained at 37 C with 5.0% CO 2 , re-fed every 2-3 days, and passaged every 7 days. For passage, medium was removed, and cells were rinsed with D-PBS and then trypsinized with 1 ml 0.25% trypsin-EDTA (Gibco) for 1-2 min before the addition of 9 ml of medium. Following centrifugation (360g, 10 min) and resuspension in new medium, the cultures were re-seeded in new T-75 culture flasks (Corning) at 0.5 million cells per flask. After a total of three passages (7, 14, 21 days), c-DDAC samples were collected at 28 days of monolayer expansion for each of the four horses.
For culture of primary bone marrow stromal cells (c-BMSCs), bone marrow aspirates were collected immediately postmortem under sterile conditions from the sternum of each horse (four horses, 1-4 years) using a Jamshidi bone marrow biopsy needle and a 60-cm 3 syringe containing 1000 units of heparin sodium solution (dilution with D-PBS of 10 000 U/ml, Baxter). Aspirates (8 ml each) were centrifuged (360g, 5 min), and cells were rinsed in D-PBS, pelleted (360g, 5 min), resuspended in 10 ml medium (OPTI-MEM, 5% fetal bovine serum, 1% L-glutamine, 25 mg/ml L-ascorbic acid phosphate, 50 U/ml penicillin, 50 mg/ml streptomycin and 1 g/ml amphotericin B), and seeded in a T-75 flask. Cells were maintained in monolayer culture at 37 C with 5.0% CO 2 . Every two days the cells were rinsed liberally with D-PBS to remove cells not adhering to the flask before adding new medium. For each horse, adherent c-BMSCs were harvested when the cells reached $80% confluence. Adherent c-BMSCs comprise a heterogeneous cell population used in autologous transplantation strategies [12, 13, 15, 16] .
RNA isolation
Neonatal articular cartilage was pulverized into powder while still frozen. The cartilage powder was then homogenized with an Ultra-Turrax T25 disperser (IKA, Wilmington, NC) on ice in a buffer of 4 M guanidinium isothiocyanate, 0.1 M Tris-HCl, 25 mM EDTA (pH 7.5) with 1% (v/v) 2-mercaptoethanol. Total RNA was isolated using phenol/chloroform extraction followed by differential alcohol and salt precipitations [20] . Finally, RNA samples were re-purified using QIAGEN RNeasy columns following the manufacturer's protocol. RNA was isolated from repair tissue samples as described in Mienaltowski et al. [7] . Total RNA was isolated from c-DDACs and c-BMSCs using the QIAGEN RNeasy Mini Kit. After cells were rinsed with D-PBS, total RNA was isolated according to manufacturer's protocol. Total RNA quantity and purity were assessed with a NanoDrop ND-1000. RNA integrity assessments were performed with a BioAnalyzer 2100 (Agilent, Eukaryotic Total RNA Nano Series II) and were deemed suitable for downstream applications based upon RNA integrity number >8, 28S:18S rRNA ratio >1.8, UV260:280 ratio >1.8, and UV260:230 ratio >1.7 (data not shown).
cDNA array
Microarray slides were printed with 9413 probe sets representing clones selected from a cDNA library generated using equine articular cartilage mRNA from a 15-month-old Thoroughbred as described in a procedure by Band et al. [7, 20, [27] [28] [29] . Nucleotide sequences for the cDNA clones can be found in GenBank accessions CX590298.1-CX606061.1. Gene identity was assigned for each microarray ID through selection of either the best RNA RefSeq BLAST (E < 1 Â 10 À7 ) or Protein RefSeq BLAST (E < 1 Â 10 À5 ) result from an internal annotation database [7, 20, 30, 31] (Supplementary  Table S1 ). Gene ontology (GO) annotation was derived from batch queries of the database for annotation, visualization and integrated discovery (DAVID) bioinformatics tool and individual NCBI Entrez Gene queries [32, 33] (Supplementary Table  S1 ). The human ortholog of each gene was predicted and used for the determination of overrepresentation of GO categories via expression analysis systematic explorer (EASE) standalone software [32, 34] .
Transcriptional profiling
Total RNA (1 mg) from each experimental sample received one round of linear amplification primed with oligo-dT (Invitrogen-SuperScript RNA Amplification System) [35, 36] . Then 1.5 mg aliquots of amplified RNA were used as a template to create fluorescent dye-coupled single-stranded aminoallylcDNA probes (Invitrogen-Superscript Indirect cDNA Labeling System, Molecular Probes-Alexa Fluor 555 and 647 Reactive Dyes). For each sample, probes were coupled to both Alexa Fluor dyes individually so that a dye swap comparison could be made between repair tissue and each of the three cell populations. Microarray slides were pre-hybridized in 20% formamide, 5Â Denhardt's, 6Â SSC, 0.1% SDS and 25 mg/ml tRNA for 45 min. Slides were washed five times in deionized water and once in isopropanol and spun dry (700g, 3 min). Two dye-coupled fluorescent cDNA probes representing one of each of the two samples (one of these cell phenotypes versus repair) were combined with 1Â hybridization buffer (Ambion, 1Â slide hybridization buffer #1, cat. no. 8801), incubated for 2 min at 95 C, and then applied to the slide under a glass lifterslip for 48 h at 42 C. All hybridizations were performed in duplicate with a dye swap to eliminate possible dye bias [37] . Post-hybridization washes were each for 5 min as follows: (i) 1Â SSC, 0.2% SDS at 42 C; (ii) 0.1Â SSC, 0.2% SDS at room temperature; (iii) and (iv) 0.1Â SSC at room temperature. After the post-hybridization washes, the slides were spun dry under argon gas (700 g, 3 min). Each slide was coated once in DyeSaver 2 (Genisphere) and allowed to dry for 10 min. Fluorescent signal was detected using a GenePix 4100A scanner and spot intensities were computed using GENEPIX 6.0 image analysis software (Axon Instruments/Molecular Devices).
Statistical analysis
Raw median intensity data adjusted for background for each probe set pair of all the microarray scans were statistically analyzed by planned linear combination [38] using SAS (SAS Institute, Cary, NC) as was described by Mienaltowski et al. [7] . Briefly, differential expression was directly compared between repair tissue cells and the three other cell types (c-BMSCs, c-DDACs and neonatal articular chondrocytes) based on a linear combination model formulation with fixed cell type and dye effect, and random chip and horse effect [7] . A dye swap design was used. Thus, for the four individual biological replicates in each comparison, the sums of the two fluorescence measurements corresponding to the cell type (Alexa Fluor 555 cell type þ Alexa Fluor 647 cell type ) were subtracted from the sum of the measurements corresponding to repair tissue (Alexa Fluor 555 repair tissue þ Alexa Fluor 647 repair tissue ). Twelve total comparisons were made representing four biological replicates per cell type. With the dye-swap, 24 slides were used. One sample t-tests were performed to determine significance of differential gene expression in each set of comparisons. Statistical data, fold change quantities and GO annotations were managed within an Excel spreadsheet (Microsoft, Redmond, WA). Microarray data are available at the NCBI Gene Expression Omnibus (GEO) under Series Accession GSE14252.
Validation of microarray hybridization results with real-time quantitative polymerase chain reactions
Differential expression was validated for five selected genes using real-time quantitative polymerase chain reactions (RT-qPCR) [7, 20] . Briefly, 200 ng total RNA from the same samples analyzed on the microarray were reverse-transcribed into cDNA using an oligo-dT primer with the Promega Reverse Transcription System (Promega, cat. no. A3500). RT-qPCR was performed using the 7900HT Fast Real-Time PCR Systems, TaqMan Gene Expression Master Mix (Applied Biosystems), and equine intron-spanning primer/probe sets (Assays-byDesign, Applied Biosystems) created from equine genomic sequence data (Ensembl-http://www .ensembl.org/Equus_caballus/index.html; UCSC Genome Browser-http://genome.ucsc.edu) (Supplementary Table S2 ). Each primer/probe set was tested for and met the specificity and performance criterion of no amplification with equine genomic DNA, minus-RT and water controls. Transcripts encoding beta-2-microglobulin (B2M) and beta-glucuronidase (GUSB) proteins were selected as endogenous controls because they showed the greatest stability for the sample set as defined by the geNorm reference gene application (data not shown) [39] . Steady-state levels of mRNA encoding proteins C-type lectin domain family 3 member A (CLEC3A), alpha-2 type I procollagen (COL1A2), alpha-1 type II procollagen (COL2A1), hyaluronan and proteoglycan link protein 1 (HAPLN1), and sex-determining region Y-box 9 (SOX9) were selected for validation (Supplementary Table S2 ). Amplification efficiencies were measured by the default fit option of LinRegPCR while maintaining the cycle threshold as a data point within the measured regression line [40] . Relative expression levels of target genes were normalized to the relative quantities of endogenous control genes using geometric averaging with the geNorm VBA applet [39] . For each gene of interest, mean fold change was determined by comparing the mean expression for each cell population as calculated by geNorm. Statistical significance of qPCR results was determined by Mann-Whitney-Wilcoxon rank sum test.
RESULTS
Overall level of differential gene expression
Differential expression was directly compared between repair tissue cells and the three other cell types (c-BMSCs, c-DDACs and neonatal articular chondrocytes). Of the three cell types being compared to repair tissue, no single sample group demonstrated similar global transcript abundance to repair tissue (Figure 1) . Instead, divergent transcriptional profiles were evident at a global level for all three cell types when compared to repair tissue. A total of 934 (9.9%), 1839 (19.5%) and 940 (10.0%) probe sets were differentially expressed for c-BMSCs, c-DDACs and neonatal articular cartilage, respectively, relative to repair tissue (P < 0.01; Supplementary Table S3 ). False discovery rates for these comparisons were estimated at 10.1% (94/ 934), 5.1% (94/1839) and 10.0% (94/940), respectively.
GO categories represented in expression analysis
For all repair tissue comparisons, an analysis of overrepresentation of GO categories via expression analysis systematic explorer (EASE) was performed for probe sets demonstrating significant differential expression (P < 0.05). Many categories typically associated with cartilaginous tissues were overrepresented by EASE analysis for groups of genes differentially expressed in either direction between the cell types and repair tissue (Supplementary Tables S4, S5 and  S6) . These included categories such as extracellular matrix, development, skeletal development, cell adhesion, cell communication, organogenesis and morphogenesis.
Cartilage biomarkers
Differences in transcript abundance for genes encoding cartilage biomarkers were evident in the three Volcano plots of probe set distributions for differential expression profiles. The volcano plots depict a divergent distribution of probe sets between repair tissue and bone marrow stem cells (c-BMSCs) (A), de-differentiated chondrocytes (c-DDACs) (B) and neonatal cartilage (C). Log 2 -fold change differences (cell type/repair tissue) of transcript abundance are represented across the horizontal axis; significance (Àlog 10 P-value) is represented across the y-axis. Significance of P ¼ 0.01 is denoted by the dashed horizontal line. The solid black line along the center of the plot represents the distinction between fold changes, or a fold difference of zero. The dashed vertical lines distinguish fold differences >2 in either direction. The probe set distribution is divided into three boxes: probe sets with P > 0.01, white box below dashed line; significant transcripts with greater abundance in repair tissue than each specific tissue, gray box; significant transcripts with greater abundance in each specific tissue relative to repair tissue, white box above dashed line.
sets of comparisons (Table 1) . Expression of alpha-1 type II procollagen (COL2A1) was greater in repair tissue relative to c-BMSCs and c-DDACs, but steady-state transcript levels were higher in neonatal articular cartilage relative to repair tissue. This same pattern (REP > c-BMSCs, REP > c-DDACs, NEO > REP) was also demonstrated for aggrecan (AGC1), type IX procollagen genes (COL9A1, COL9A2, COL9A3), hyaluronan and proteoglycan link protein 1 (HAPLN1), proteoglycan 4 or superficial zone protein (PRG4 or SZP), cartilage oligomeric matrix protein (COMP), tenascin-C (TNC), frizzled-related protein (FRZB) and sex-determining region Y-box 9 (SOX9). However, probe sets representing other procollagen genes (COL1A1, COL1A2, COL5A1, COL5A2, COL6A1, COL6A2 and COL12A1) typically used to describe fibrocartilage expression patterns demonstrated few significant differences. Of the cartilage biomarker probe sets demonstrating significant differential expression, the most common pattern was up-regulation in repair tissue relative to DDCs and BMSCs and down-regulation in repair tissue relative to neonatal articular cartilage. Moreover, probe sets representing genes that are biomarkers of the chondrocytic phenotype or differentiation status were amongst those with the greatest fold differences for these comparisons (Table 2 ). For example, HAPLN1 transcripts demonstrated the greatest measurable fold difference amongst the three comparisons by 422Â and 354Â (P < 0.01) for repair tissue over c-BMSCs via hybridization to two probe sets (CX599739.1 and For each gene symbol within a function category, total numbers of probe sets on the microarray are indicated. In the table, the following designations are made: REP, repair tissue; c-BMSCs, bone marrow stromal cells; c-DDACs, de-differentiated chondrocytes; NEO, neonatal articular cartilage. 'Median fold difference' is the median expressional difference between the cell type listed in the column versus repair tissue, in consideration of all probe sets for that gene symbol ('total probe sets'). Probe sets with a significance of P < 0.01 are tallied for each comparison in the 'P < 0.01' column. Those probe sets with a P < 0.05 are counted in the 'P < 0.05' with values under 0.01 already recorded in the 'P < 0.01' column.
CX593615.1, respectively)
. Hybridization differences were also great for probe sets of C-type lectin superfamily 3 domain A with a 310Â-fold difference noted for one probe set (CX592936.1, P < 0.01) for repair tissue transcripts over those of c-BMSCs. From these results, it is clear that transcripts of matrix biomarkers contribute to clear distinctions in the phenotypes of the cell populations examined.
Growth factors
In the microarray hybridizations, differential gene expression (P < 0.05) was noted for growth factors, particularly within the TGFb, IGF and FGF superfamilies. However, the magnitude of differential expression did not approach the differences demonstrated for cartilage matrix proteins. Transcripts of bone morphogenetic protein 2 (BMP2) were slightly more abundant in repair tissue relative to c-BMSCs and c-DDACs in two of the six probe sets on the array while similarly expressed when compared to neonatal articular cartilage (Table 3) . Expression for growth differentiation factor 6 (GDF6) was up-regulated in c-DDACs and neonatal articular cartilage relative to repair tissue. Transcript levels of transforming growth factor beta receptors 2 and 3 Gene name and gene symbol were determined for each probe set (identified by Genbank ID) spotted on the array.'Comparison'described the arrays comparing repair (REP) tissue to one of the three other cell types (c-BMSCs: bone marrow stromal cells; c-DDACs: de-differentiated chondrocytes; NEO: neonatal articular cartilage).'Fold difference' describes the mean fold difference measured for that one probe set in the four replicates for a comparison with the statistical significance determined by t-test and reported as 'P-value'.
(TGFBR2 and TGFBR3) were up-regulated in neonatal articular cartilage relative to repair tissue, and TGFBR3 transcripts were also more abundant in c-DDACs than in repair tissue. Basic fibroblast growth factor (FGF2) expression was slightly increased in repair tissue relative to all three cell populations compared, and FGF10 expression was increased in repair tissue relative to c-DDACs and neonatal articular cartilage. 
RT-qPCR validation
RT-qPCR was used to measure steady-state transcript abundance for endogenous controls beta-2-microglobulin (B2M) and beta-glucuronidase (GUSB), as well as target genes C-type lectin For each gene symbol within a function category, total numbers of probe sets on the microarray are indicated. In the table, the following designations are made: REP, repair tissue; c-BMSCs, bone marrow stromal cells; c-DDACs, de-differentiated chondrocytes; NEO, neonatal articular cartilage. 'Median fold difference' is the median expressional difference between the cell type listed in the column versus repair tissue, in consideration of all probe sets for that gene symbol ('total probe sets'). Probe sets with a significance of P < 0.01 are tallied for each comparison in the 'P < 0.01' column. Those probe sets with a P < 0.05 are counted in the 'P < 0.05' with values under 0.01 already recorded in the 'P < 0.01' column.
domain family 3 member A (CLEC3A), alpha-2 type I procollagen (COL1A2), alpha-1 type II procollagen (COL2A1), hyaluronan and proteoglycan link protein 1 (HAPLN1) and sex-determining region Y-box 9 (SOX9) ( Table 4 ). Fold change differences were similar or greater than what was measured by microarray profiles. Disparities in magnitude of expression between hybridizationand amplification-based assays occurred because of differences in sensitivity and thus dynamic range, which result from technical differences between the assays [41] . Relative quantification of target transcripts revealed significant increases in mRNA abundance for CLEC3A, COL2A1 and HAPLN1 in repair tissue and neonatal articular cartilage with little to no expression in c-DDACs and c-BMSCs. Moreover, COL2A1 and HAPLN1 expression was greater in neonatal articular cartilage relative to repair tissue. COL1A2 transcript abundance was more stable in the four sample sets, with a significant difference limited to higher levels in c-DDACs relative to neonatal articular cartilage. Finally, SOX9 transcript abundance was greatest in neonatal articular cartilage. Expression levels for SOX9 were found to be greater in c-BMSCs and c-DDACs than in repair tissue by RT-qPCR, though this contradicts microarray results which may be less reliable due to low SOX9 mRNA levels (Table 1) .
DISCUSSION
In this study, we set out to examine three questions: (i) Does the expression profile of repair tissue broadly match one of the three cell populations compared? (ii) How do the transcriptional profiles of de-differentiated chondrocytes and BMSCs pretransplantation compare to that of repair tissue? (iii) Which biomarkers distinguish the highly anabolic cells in neonatal articular cartilage from those of repair tissue? Broadly, the transcriptional profiles indicated that the three cell populations are quite dissimilar to repair tissue at the transcriptional level. That is, roughly 10-20% of the probe sets demonstrated differential expression. Many of the probe sets with the greatest expression differences represented biomarkers that define the phenotype of cartilaginous tissues, such as skeletal development, cell adhesion and extracellular matrix proteins. The data do not suggest that any one of the tissues studied closely resemble repair tissue at the 4-month time point. The data do, however, provide novel insight into the differentiation status of the cells in repair tissue as well as three other tissues compared.
The genes encoding many cartilage matrix proteins (COMP, AGC1, HAPLN1, COL2A1, COL9A1, COL9A2 and COL9A3) exhibited a similar relative pattern of transcript abundance: neonatal articular cartilage > repair tissue > bone marrow stromal cells (c-BMSCs) ¼ de-differentiated chondrocytes (c-DDACs). Thus, while fold differences might lead to a conclusion that repair tissue at the 4-month post-operative time-point is more closely related to neonatal cartilage than c-DDACs and c-BMSCs, the great disparity in expression levels of these matrix proteins in neonatal cartilage and repair tissue indicate otherwise. For example, repair cells produce 15-fold less HAPLN1 transcripts and 56-fold less COL2A1 transcripts than neonatal articular chondrocytes by RT-qPCR (Table 4) . Hence, while parallels might be drawn as a result of the increased transcript abundance relative to c-DDACs and primary c-BMSCs, it is clear that the cells in repair tissue have not achieved the same level of chondrogenic differentiation as chondrocytes in neonatal articular cartilage. The same could be said about the monolayer culture-expanded c-DDACs and c-BMSCs. Thus, current therapeutic strategies utilizing these cell populations will require supplemental methods to be optimized and applied in order to stimulate the transplanted cells to create cartilage [21] [22] [23] .
In examining genes with the greatest differential expression, a gene encoding a tetranectin-like protein, C-type lectin domain family 3 member A (CLEC3A), demonstrated the second highest level of differential expression behind HAPLN1 amongst the microarray-based comparisons. A distinct pattern of expression was confirmed for CLEC3A by RT-qPCR (Table 4) . That is, there was no significant difference between repair tissue and neonatal articular cartilage. Interestingly, however, there was no expression detected in c-BMSCs and c-DDACs. While this gene is thought to encode a cartilagederived lectin, its exact function has yet to be ascertained. Lectins serve as glycan binding proteins and are involved in cell adhesion, recognition of self and molecular trafficking, and receptor activation [42] . Considering the role of glycosaminoglycan binding in the formation of the extracellular matrix and cell/ matrix interactions, further studies of this gene appear justified since its expression seems to depend upon whether the cells exist within a tissue or have been maintained in culture. From these data, it appears that CLEC3A could encode a novel biomarker useful to assess cartilage phenotype.
Measurements of differential expression for genes encoding growth factors and their receptors revealed several interesting associations (Table 3 ). All three comparisons to repair tissue revealed little to no differences for TGFb superfamily members, though betaglycan (TGFBR3) transcripts had greater abundance in cells present in tissues as opposed to cultured cells. Betaglycan acts to sequester growth factors within the cartilage matrix when secreted and also recruits TGFb superfamily ligands to chondrocytes if localized to the cell membrane [43] . Such ligands are considered essential to chondrogenesis or chondroprotection [44] [45] [46] ; results of this study are supportive of such roles for TGFBR3. Since IGFBP4 encodes an established biomarker for c-BMSCs, it is not surprising that increased transcript abundance was higher in these cells than in repair tissue, which had expression levels equivalent to those of neonatal articular cartilage and c-DDACs [47] . In fact, expression amongst growth factor associated genes was greatest for IGFBP4 in c-BMSCs. Repair cells did exhibit greater transcript abundance for fibroblast growth factors 2 and 10 (FGF2, FGF10), consistent with a functional role in wound healing [48, 49] . FGFR3 expression was comparable in repair tissue and neonatal articular cartilage, but lower in c-BMSCs and c-DDACs. The receptor has an important role in FGF activation of type II collagen and proteoglycan synthesis [50, 51] . Taken together, however, there was no specific expression of a growth factor receptor gene that seemed to point to a crucial mechanism or signature relating repair cells to any one cell population in this study. It appears that the cells of repair tissue are transcribing genes that could improve their chondrogenic status while simultaneously expressing factors and receptors responsible for wound healing. Assessment of the role of specific growth factors in the differentiation of stromal cells and chondrocytes is confounded by the utilization in many culture protocols of fetal bovine serum which contains varying levels of growth factors from sample lot to lot and manufacturer to manufacturer. With all of the current literature demonstrating the importance of growth factors and their receptors in regards to chondrogenic differentiation status, it is possible that more substantial differences are present at a post-transcriptional level [51] [52] [53] [54] . Determination of the contribution of growth factors to the repair process will be better resolved by time course analyses of articular lesions on both transcriptional and translational levels, and by specifically examining the addition or deficiency of individual factors under defined medium conditions.
Results of this study illustrate the challenges faced in trying to understand dynamic relationships in the healing process of articular cartilage lesions. Repair tissue was collected at a single 4-month time-point in a multi-step repair process. The BMSCs which enter a full-thickness lesion extending into the subchondral bone include stromal fibroblasts, histiocytes, endothelial cells, as well as erythroid and myeloid precursors. The repair tissue samples might also have contained small amounts of surrounding normal articular cartilage. Likewise, the multiple colony-forming c-BMSCs adhering to the culture flask are also heterogeneous [55] . Tissue heterogeneity can amplify or dampen gene expression profiles as one population of cells might contribute to the levels of transcript detected. Additionally, repair tissue was compared to cells expanded in culture. Variations in gene expression have been demonstrated to be confluency-, seeding density-and growth factor-dependent [56] . Thus, cell proliferation in an expansive culture, particularly when utilizing fetal bovine serum, might not be an analogous model to the biological status of repair tissue at 4 months into the healing process. This is especially true if one notes that cell expansion in a full-thickness lesion has been described at earlier time points [2, 3, 6, 24] . Different levels of healing might be the result of variations of culture conditions, cell populations, or niche components utilized in autologous cell therapies [10] . Future studies to better characterize the cells of repair tissue would benefit from having more time points throughout the repair process of a full-thickness lesion and thus better resolution of the cell populations associated with repair. In addition, examination of the effect of specific growth factor supplementation should be included to better determine how best to improve autologous cell strategies. These same biological considerations should be made by orthopaedic surgeons who utilize tissue engineering to repair articular lesions. Additional information is needed to determine how to effectively drive both natural and engineered repair tissue toward a more chondrogenic phenotype.
CONCLUSIONS
Based on transcriptional profiling, no specific pre-transplantation cell type demonstrated an expression pattern highly concordant to articular repair tissue harvested at a 4-month post-operative time-point. Broad differences in gene expression were observed between the repair tissue and neonatal articular cartilage, chondrocytes de-differentiated in monolayer culture, and BMSCs isolated by adherent culture. Moreover, in each comparison to repair tissue, the greatest expression differences were detected for genes within the skeletal development, cell adhesion, and extracellular matrix ontological categories. Many transcripts encoding cartilage matrix protein biomarkers demonstrated high levels of differential expression. Such clear differences in gene expression indicate the necessity to determine how the cells in repair tissues, natural or engineered, can be directed more successfully towards chondrogenic differentiation. Future studies should include the systematic examination of tissue engineering outcomes from alterations of cell populations, specific growth factors, and niche components like natural or synthetic scaffolds.
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